Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.

But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.

The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.

But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.

In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.